Obesity and Leptin Resistance in the Regulation of the Type I Interferon Early Response and the Increased Risk for Severe COVID-19

dc.contributor.authorMuskiet, Frits A. J.
dc.contributor.authorCarrera Bastos, Pedro
dc.contributor.authorPruimboom, Leo
dc.contributor.authorLucía Mulas, Alejandro
dc.contributor.authorFurman, David
dc.date.accessioned2022-05-25T09:43:38Z
dc.date.available2022-05-25T09:43:38Z
dc.date.issued2022
dc.description.abstractObesity, and obesity-associated conditions such as hypertension, chronic kidney disease, type 2 diabetes, and cardiovascular disease, are important risk factors for severe Coronavirus disease-2019 (COVID-19). The common denominator is metaflammation, a portmanteau of metabolism and inflammation, which is characterized by chronically elevated levels of leptin and pro-inflammatory cytokines. These induce the “Suppressor Of Cytokine Signaling 1 and 3” (SOCS1/3), which deactivates the leptin receptor and also other SOCS1/3 sensitive cytokine receptors in immune cells, impairing the type I and III interferon early responses. By also upregulating SOCS1/3, Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 adds a significant boost to this. The ensuing consequence is a delayed but over-reactive immune response, characterized by high-grade inflammation (e.g., cytokine storm), endothelial damage, and hypercoagulation, thus leading to severe COVID-19. Superimposing an acute disturbance, such as a SARS-CoV-2 infection, on metaflammation severely tests resilience. In the long run, metaflammation causes the “typical western” conditions associated with metabolic syndrome. Severe COVID-19 and other serious infectious diseases can be added to the list of its short-term consequences. Therefore, preventive measures should include not only vaccination and the well-established actions intended to avoid infection, but also dietary and lifestyle interventions aimed at improving body composition and preventing or reversing metaflammation.spa
dc.description.filiationUEMspa
dc.description.impact5.9 Q1 JCR 2022spa
dc.description.impact1.291 Q1 SJR 2022spa
dc.description.impactNo data IDR 2022spa
dc.description.sponsorshipSin financiaciónspa
dc.identifier.citationMuskiet, F., Carrera-Bastos, P., Pruimboom, L., Lucía, A., & Furman, D. (2022). Obesity and Leptin Resistance in the Regulation of the Type I Interferon Early Response and the Increased Risk for Severe COVID-19. Nutrients, 14(7), 1388. https://doi.org/10.3390/nu14071388spa
dc.identifier.doi10.3390/nu14071388
dc.identifier.issn2072-6643
dc.identifier.urihttp://hdl.handle.net/11268/11296
dc.language.isoengspa
dc.peerreviewedSispa
dc.rightsAtribución 4.0 Internacional*
dc.rights.accessRightsopen accessspa
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.otherCOVID-19spa
dc.subject.unescoObesidadspa
dc.subject.unescoEfectos fisiológicosspa
dc.subject.unescoVirusspa
dc.titleObesity and Leptin Resistance in the Regulation of the Type I Interferon Early Response and the Increased Risk for Severe COVID-19spa
dc.typejournal articlespa
dspace.entity.typePublication
relation.isAuthorOfPublicationd3691359-d7bd-4a12-b84e-338e28c81f9f
relation.isAuthorOfPublication.latestForDiscoveryd3691359-d7bd-4a12-b84e-338e28c81f9f

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Lucía_Nutrients_2022.pdf
Size:
1.48 MB
Format:
Adobe Portable Document Format
Description:
Versión del editor